Provided by Tiger Trade Technology Pte. Ltd.

HAIXI PHARMA

201.000
-3.200-1.57%
Volume:105.00K
Turnover:21.02M
Market Cap:15.82B
PE:67.55
High:204.200
Open:201.000
Low:196.600
Close:204.200
52wk High:302.400
52wk Low:97.500
Shares:78.71M
HK Float Shares:78.71M
Volume Ratio:0.37
T/O Rate:0.13%
Dividend:- -
Dividend Rate:- -
EPS(LYR):2.976
ROE:16.58%
ROA:9.23%
PB:8.51
PE(LYR):67.55
PS:23.28

Loading ...

Humanoid Robot Output Ramps Up as Oil and Gas 15th Five-Year Plan Takes Shape

Stock News
·
Aug 18

HAIXI PHARMA Gains US FDA Fast Track Status for Lead Candidate Targeting Wet AMD

Stock News
·
Aug 17

Fujian Haixi Pharma Says FDA Grants Fast Track Status to Hx9428 for Wet AMD

Reuters
·
Aug 17

Fujian Haixi Pharmaceuticals Co - Hx9428 Granted Fast Track Designation by U.S. FDA for Neovascular Age-Related Macular Degeneration

THOMSON REUTERS
·
Aug 17

Haixi Pharma Sets 28 Aug 2026 Board Meeting to Approve 1H26 Results and Discuss Interim Dividend

Bulletin Express
·
Aug 12

Fujian Haixi Pharmaceuticals Schedules Board Meeting to Review Interim Results

Reuters
·
Aug 12

Haixi Pharma Discloses Detailed Rationale and Timeline for Replacing Deloitte with RSM as External Auditor

Bulletin Express
·
Aug 11

Fujian Haixi Pharma Clarifies Auditor Switch Driven by CASBE Reporting Demands, not Deloitte Dispute

Reuters
·
Aug 11

Fujian Haixi Jumps on Initial Approval of Hx9428 for Macular Degeneration Treatment

Reuters
·
Aug 05

Haixi Pharma Shares Surge Over 14% on US FDA Approval for Phase 2 Clinical Trial of HX9428

Deep News
·
Aug 05

Haixi Pharma secures FDA clearance for HX9428 Phase II nAMD trial and launches parallel study in China

Bulletin Express
·
Aug 04

HAIXI PHARMA Advances Oral nAMD Treatment with FDA Trial Approval and New Chinese Study

Stock News
·
Aug 04

Fujian Haixi Pharma Wins FDA IND Clearance for Hx9428 Phase II nAMD Trial

Reuters
·
Aug 04

Fujian Haixi Pharmaceuticals Co - U.S. FDA Approves Ind Application of Hx9428 for Neovascular Age-Related Macular Degeneration

THOMSON REUTERS
·
Aug 04

Personnel Shake-up at HAIXI PHARMA: New Executive Director Appointed

Stock News
·
Aug 04

Fujian Haixi Pharma Shareholders Approved External Auditor Change at EGM

Reuters
·
Aug 04

Fujian Haixi Pharmaceuticals Files Board, Board Committee Member List with Disclosure Roles

Reuters
·
Aug 04

Fujian Haixi Pharmaceuticals Co - Elects Chen Tingze as Executive Director

THOMSON REUTERS
·
Aug 04

Fujian Haixi Pharma Discloses RMB 577.22 Million Investments Equal to 31.3% of 2025 Total Assets

Reuters
·
Aug 03

Hong Kong Market Midday Update: Hang Seng Index Edges Up Slightly, Chip Stocks Lead Gains

Stock News
·
Jul 21